Precision Medicine plays a vital role in identifying appropriate patients for new targeted therapies across multiple specialties. Amplity has unique experience and expertise in developing launch strategies – aligning, optimizing and operationalizing the commercial components of a diagnostic to your therapy. We’ve supported Companion Diagnostic launches across 17 different indications, with 7 unique biomarkers, using 6 customized methodologies.
Our flexible, global solutions help eliminate operational barriers around testing, create advocacy for your therapy, and mobilize the multi-disciplinary process to drive behavior change.
Virtual Diagnostic Center
A global resource for strategic planning, the VDC quantifies specific, account level detail to optimize development and launch strategies
Laboratory Science Liaisons
Increase disease state awareness and collect meaningful insights, and support quality testing initiatives with dedicated non-promotional laboratory specialist teams
Companion Diagnostic Commercialization
Our Precision Medicine experts have created an eco-system that focuses specifically on delivering operational elements required for optimal companion diagnostic market execution.
Hands on, end-to-end advisory services to support planning and executional strategy
Oncology Diagnostic Manager
Dedicated promotional field commercial teams focused on laboratory medical specialists to optimize operational components of testing
Amplity’s VP of Precision Medicine and Companion Diagnostics, Ken Ruppel, discusses the four simple areas that must be considered when launching a precision medicine therapy: why, when, what, and who.Learn More
Read our white paper for a quick history on the challenges aligning a diagnostic to a therapy has created for Pharma along with a few suggestions on how to improve the process.Learn More
Amplity’s Precision Medicine team provides expertise throughout the product life cycle, including but not limited to consultative support, medical affairs, commercial and Key Opinion Leader (KOL) networks. Our deep relationships with National and Regional Reference laboratories and University and Community pathologists create instant access to key players in the multidisciplinary process-pre and post-launch. Our colleagues amplify your diagnostic strategy and execution, optimizing your therapeutic launch.
We have supported successful Companion Diagnostic launches across several tumor types, disease states, and methodologies. As a result, we have first-hand evidence proving that when a diagnostic and therapy are aligned, therapeutic uptake is accelerated.
Interested in learning more? Click here for a case study on how our Laboratory Science Liaisons supported testing a novel biomarker for a new Companion Diagnostic.